Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
77 hedge funds and large institutions have $327M invested in Repare Therapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 25 reducing their positions, and 12 closing their positions.
106% more call options, than puts
Call options by funds: $175K | Put options by funds: $85K
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.79% less ownership
Funds ownership: 79.69% → 78.91% (-0.79%)
6% less funds holding
Funds holding: 82 → 77 (-5)
20% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 25
33% less capital invested
Capital invested by funds: $491M → $327M (-$164M)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.55M |
| 2 |
SCM
Sio Capital Management
New York
|
+$2.62M |
| 3 |
CA
CHI Advisors
New York
|
+$2.27M |
| 4 |
Renaissance Technologies
New York
|
+$764K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$667K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$2.79M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$2.12M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.1M |
| 4 |
Millennium Management
New York
|
-$2.01M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.74M |
RPTX Hedge Fund Activity: Q1 2023 in Review
77 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q1 2023, worth a combined $327M — down 33% from $491M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RPTX and 7 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 20 added.
The largest buyer was ARK Investment Management, adding an estimated $3.55M. The largest seller was Bank of America, cutting an estimated $2.79M.
- 77 institutional investors held Repare Therapeutics (RPTX) as of Q1 2023, down from 82 in Q4 2022.
- Funds reported $327M of Repare Therapeutics stock for Q1 2023, down 33% quarter-over-quarter.
- 7 funds opened new Repare Therapeutics positions in Q1 2023 and 12 closed out, a net change of -5 holders.
- The largest Repare Therapeutics buyer in Q1 2023 was ARK Investment Management, an estimated $3.55M added.
- The largest Repare Therapeutics seller in Q1 2023 was Bank of America, an estimated $2.79M sold.
Based on aggregated 13F filings for Q1 2023.